The challenges of developing new tuberculosis vaccines

Health Affairs

Volumn 30, Issue 6, 2011, Pages 1073-1079

  Barker, Lewellys F ^a   Leadman, Annmarie E ^a   Clagett, Bartholt ^a  

^a AERAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG85B EARLY SECRETORY ANTIGENIC TARGET 6 FUSION PROTEIN; AG85B TB10 4 FUSION PROTEIN; BCG VACCINE; IMMUNOLOGICAL ADJUVANT; IMMUNOLOGICAL ADJUVANT AS01; IMMUNOLOGICAL ADJUVANT CAF01; IMMUNOLOGICAL ADJUVANT IC31; MTB 39 MTB 32 FUSION PROTEIN; RECOMBINANT PROTEIN AG85A; RECOMBINANT PROTEIN AG85B; RECOMBINANT PROTEIN RV3407; UNCLASSIFIED DRUG;

ARTICLE; BCG VACCINATION; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG SYNTHESIS; ECONOMIC ASPECT; GENETIC ANALYSIS; HEALTH CARE POLICY; HUMAN; IMMUNE RESPONSE; IMMUNITY; INNATE IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLITICS; PUBLIC-PRIVATE PARTNERSHIP; TUBERCULOSIS; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION;

COOPERATIVE BEHAVIOR; DRUG APPROVAL; HUMANS; MYCOBACTERIUM; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 79959491421     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.0303     Document Type: Article

References (19)

1. World Health Organization. Global tuberculosis control 2010 [Internet]. Geneva: WHO; 2010 [cited 2011 Mar 7]. Available from: http://www.who.int/tb/publications/global_report/2010/en/index.html.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global burden of disease and risk factors. Washington (DC): World Bank; 2006.
3. Russell S. The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis, and human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop Med Hyg. 2004; 71(2 Suppl):147-55.
4. Laxminarayan R, Klein EY, Darley S, Adeyi O. Global investments in TB control: economic benefits. Health Aff (Millwood). 2009;28(4):w730-42. DOI: 10.1377/hlthaff.28.4.w730.
5. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response [Internet]. Geneva: WHO; 2010 [cited 2011 Mar 7]. Available from: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf.
6. There are several BCG strains that vary in genetic makeup due to continuous subculture across laboratory locations since BCG was first developed. For the purposes of this paper, we refer to a singular BCG vaccine.
7. Stop TB Partnership. The global planto stop TB, 2006-2015. Geneva: World Health Organization; 2006.
8. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM Jr., Dye C, et al. Epidemiological benefits of moreeffective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A. 2009;106(33): 13980-5.
9. Bishai DM, Mercer D. Modeling the economic benefits of better TB vaccines. Int J Tuberc Lung Dis. 2001; 5(11):984-93.
10. Tseng CL, Oxlade O, Menzies D, Aspler A, Schwartzman K. Costeffectiveness of novel vaccines for tuberculosis control: a decision analysis study. BMC Public Health. 2011;11(1):55.
11. Barker LF, Brennan MJ, Rosenstein PK, Sadoff JC. Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol. 2009;21(3): 331-8.
12. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol. 2006;4(6):469-76.
13. Boosting BCG with BCG does not appear to provide improved protection. Although revaccination with BCG has been practiced in some countries in the past, it is not recommended by the World Health Organization.
14. Meeting of the immunization Strategic Advisory Group of Experts, April 2007-conclusions and recommendations. Wkly Epidemiol Rec.2007;82(21):181-93.
15. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet. 2010;375(9731):2110-9.
16. Shah R, David E. Remarks by USAID administrator Dr. Rajiv Shah [Internet]. Washington (DC): National Institutes of Health; 2011 [cited 2011 May 23]. Available from: http://www.usaid.gov/press/speeches/2011/sp110215.html.
17. Stop TB Partnership. The global plan to stop TB (2011-2015) [Internet]. Geneva: World Health Organization; 2010 [cited 2011 Mar 4]. Available from: http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf.
18. Jimenez Salazar E. Tuberculosis research and development: 2010 report on tuberculosis research funding trends, 2005-2009 [Internet]. New York (NY): Treatment Action Group; 2010 [cited 2011 May 31]. Available from: http://www.stoptb.org/assets/documents/resources/publications/technical/TB%20R_D%202010%20Report%202nd%20Edition.pdf.
19. Moran M, Guzman J, Henderson K, Abela-Oversteegen L, Wu L, Omune B, et al. Neglected disease research and development: is the global financial crisis changing R&D? [Internet]. London: Policy Cures; 2010 [cited 2011 Apr 7]. Available from: http://www.edctp.org/fileadmin/documents/g-finder_2010.pdf.